Overview
- Eli Lilly’s tirzepatide posted Rs 80 crore in September revenue in India, second only to GSK’s Augmentin at Rs 85 crore, with cumulative sales reaching roughly Rs 233 crore since launch.
- Market trackers attribute the jump to dose escalation after four weeks of therapy, strong new patient starts, and CDSCO approval of a ready‑to‑use prefilled KwikPen; monthly costs are reported around Rs 14,000–17,500 for available doses.
- By volume, Mounjaro has overwhelmingly outpaced Novo Nordisk’s Wegovy in India, exceeding 96% share in reported periods as Wegovy’s monthly sales hovered near Rs 9 crore with unit volumes plateauing.
- Pharmarack notes value leadership is driven by pricing rather than volume, with analysts warning rankings could shift as competition and potential semaglutide generics arrive before tirzepatide faces patent expiry.
- Wales has created a task group to plan scalable NHS access to tirzepatide‑class drugs, keeping prescribing largely within specialist services for now, whereas England has allowed limited GP prescribing for prioritised patients.